Skip to main content
Top
Published in: Advances in Therapy 10/2016

01-10-2016 | Original Research

Pharmacokinetic Properties of Oral Lafutidine Tablets and the Effect of Food on its Pharmacokinetics in Healthy Chinese Subjects

Authors: Shihong Li, Mingzhen Xu, Huqun Li, Juan Du, Weiyong Li

Published in: Advances in Therapy | Issue 10/2016

Login to get access

Abstract

Introduction

The aim of this study was to evaluate the pharmacokinetics (PK) of single and multiple doses of oral lafutidine tablets and the effect of food on the PK properties in healthy Chinese subjects. The tolerability and the effect of gender on the PK properties were also evaluated to acquire more PK information.

Methods

Three PK studies were conducted in 12 healthy Chinese subjects (6 male, 6 female). Study 1 was a single-dose, three-period, three-dose level (10, 20, and 40 mg), three-sequence cross-over study under fasting conditions. Study 2 was a repeat-dose study (10 mg twice daily over 6 days; all 12 subjects). Study 3 was a two-period, two-sequence cross-over single-dose (10 mg) food interaction study. All randomizations (study 1, study 3) were done to ascertain 1:1 gender ratio per sequence. A validated liquid chromatography tandem mass spectrometry (LC/MS/MS) method was used to determine plasma lafutidine concentrations. PK parameters were calculated by the non-compartmental method.

Results

The area under the time–concentration curve (AUC) and maximum plasma concentration (C max) of lafutidine tablets were dose-independent in the single-dose study among these healthy volunteers. The PK parameters of the multiple-dose study were inconsistent with the single study. After administration of a single dose of 10 mg under either fed or fasting conditions, we found that food may not affect the degree of absorption of the lafutidine tablets, but it may slow down the absorption rate. This is shown by the fact that the AUC showed no significant difference while the peak time was significantly delayed under fed conditions.

Conclusion

The PK of lafutidine showed dose proportionality. There was no significant accumulation of lafutidine tablets with multiple dosing. Food did not affect the degree of lafutidine absorption, but it did reduce the rate of absorption. Further study is needed regarding the effect of gender on lafutidine. Lafutidine was well tolerated within the dose range 10–40 mg, and no serious adverse events were observed.
Literature
1.
go back to reference Chen Wei-Dong, Liang Yan, et al. Simple, sensitive and rapid LC–ESI–MS method for the quantitation of lafutidine in human plasma—application to pharmacokinetic studies. J Pharm Biomed Anal. 2006;41:256–60.CrossRefPubMed Chen Wei-Dong, Liang Yan, et al. Simple, sensitive and rapid LC–ESI–MS method for the quantitation of lafutidine in human plasma—application to pharmacokinetic studies. J Pharm Biomed Anal. 2006;41:256–60.CrossRefPubMed
2.
go back to reference Onodera S, Shibata M, Tanaka M, Inaba N, Yamaura T, Ohnishi H. Gastroprotective activity of FRG-8813, a novel histamine H2-receptor antagonist, in rats. Jpn J Pharmacol. 1995;68:161–73.CrossRefPubMed Onodera S, Shibata M, Tanaka M, Inaba N, Yamaura T, Ohnishi H. Gastroprotective activity of FRG-8813, a novel histamine H2-receptor antagonist, in rats. Jpn J Pharmacol. 1995;68:161–73.CrossRefPubMed
3.
go back to reference Ren Q, Ma B, Yang K, Yan X. Lafutidine-based triple therapy for Helicobacter pylori eradication. Hepatogastroenterology. 2010;57:102–3. Ren Q, Ma B, Yang K, Yan X. Lafutidine-based triple therapy for Helicobacter pylori eradication. Hepatogastroenterology. 2010;57:102–3.
4.
go back to reference Shibata M, Yamaura T, Inaba N, Onodera S, Chida Y, Ohnishi H. Gastric anti-secretory effect of FRG-8813, a new histamine H2 receptor antagonist, in rats and dogs. Eur J Clin Pharmacol. 1993;235:245.CrossRef Shibata M, Yamaura T, Inaba N, Onodera S, Chida Y, Ohnishi H. Gastric anti-secretory effect of FRG-8813, a new histamine H2 receptor antagonist, in rats and dogs. Eur J Clin Pharmacol. 1993;235:245.CrossRef
5.
go back to reference Yamaura T, Shibata M, Inaba N, Onodera S, Chida Y, Ohnishi H. Effects of FRG-8813, a new-type histamine H2 receptor antagonist, on various experimental gastric and duodenal lesions in rats. Nippon Yakurigaku Zasshi. 1992;99:401.CrossRefPubMed Yamaura T, Shibata M, Inaba N, Onodera S, Chida Y, Ohnishi H. Effects of FRG-8813, a new-type histamine H2 receptor antagonist, on various experimental gastric and duodenal lesions in rats. Nippon Yakurigaku Zasshi. 1992;99:401.CrossRefPubMed
6.
go back to reference Lili Wu, Zhang Zunjian, et al. Determination of lafutidine in human plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry: application to a bioequivalence study. J Mass Spectrom. 2005;40:1637–43.CrossRef Lili Wu, Zhang Zunjian, et al. Determination of lafutidine in human plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry: application to a bioequivalence study. J Mass Spectrom. 2005;40:1637–43.CrossRef
7.
go back to reference Saegusa Y, Ichikawa T, Iwai T, et al. Effects of acid antisecretory drugs on mucus barrier of the rat against 5-fluorouracil-induced gastrointestinal mucositis. Scand J Gastroenterol. 2008;43:531–7.CrossRefPubMedPubMedCentral Saegusa Y, Ichikawa T, Iwai T, et al. Effects of acid antisecretory drugs on mucus barrier of the rat against 5-fluorouracil-induced gastrointestinal mucositis. Scand J Gastroenterol. 2008;43:531–7.CrossRefPubMedPubMedCentral
8.
go back to reference Kim EH, et al. Efficacy of lafutidine versus famotidine in patients with reflux esophagitis: a multi-center, randomized, double-blind, non-inferiority phase III trial. Dig Dis Sci. 2015;60:1724–1732. Kim EH, et al. Efficacy of lafutidine versus famotidine in patients with reflux esophagitis: a multi-center, randomized, double-blind, non-inferiority phase III trial. Dig Dis Sci. 2015;60:1724–1732.
9.
go back to reference Namikawa T, et al. Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer. Anticancer Res. 2014;34(12):7297–301.PubMed Namikawa T, et al. Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer. Anticancer Res. 2014;34(12):7297–301.PubMed
10.
go back to reference Yamamoto H, et al. Changes in the mucus barrier during cisplatin-induced intestinal mucositis in rats. Biomed Res Int. 2013;2013:276186.PubMedPubMedCentral Yamamoto H, et al. Changes in the mucus barrier during cisplatin-induced intestinal mucositis in rats. Biomed Res Int. 2013;2013:276186.PubMedPubMedCentral
11.
go back to reference Nagano H, Sanai H, Muraoka M, Takagi K. Efficacy of lafutidine, a histamine H2-receptor antagonist, for taxane-induced peripheral neuropathy in patients with gynecological malignancies. Gynecol Oncol. 2012;127(1):172–4.CrossRefPubMed Nagano H, Sanai H, Muraoka M, Takagi K. Efficacy of lafutidine, a histamine H2-receptor antagonist, for taxane-induced peripheral neuropathy in patients with gynecological malignancies. Gynecol Oncol. 2012;127(1):172–4.CrossRefPubMed
12.
go back to reference Ikawa K, Shimatani T, et al. Pharmacokinetic and pharmacodynamic properties of lafutidine after postprandial oral administration in healthy subjects: comparison with famotidine. Biol Pharm Bull. 2007;30(5):1003–6.CrossRefPubMed Ikawa K, Shimatani T, et al. Pharmacokinetic and pharmacodynamic properties of lafutidine after postprandial oral administration in healthy subjects: comparison with famotidine. Biol Pharm Bull. 2007;30(5):1003–6.CrossRefPubMed
13.
go back to reference Dewan B, Chimata R, et al. An open-label, randomized, cross-over bioequivalence study of lafutidine 10 mg under fasting condition. World J Gastrointest Pharmacol Ther. 2010;1(5):112–8.CrossRefPubMedPubMedCentral Dewan B, Chimata R, et al. An open-label, randomized, cross-over bioequivalence study of lafutidine 10 mg under fasting condition. World J Gastrointest Pharmacol Ther. 2010;1(5):112–8.CrossRefPubMedPubMedCentral
14.
go back to reference Haruki S, Matsumoto H, Kodama K, Tanabe M, Takayanagi H, Cyong J, et al. Pharmacokinetic studies of lafutidime (FRG–8813) in man. Jpn Pharmacol Ther. 1995;23:3049–59. Haruki S, Matsumoto H, Kodama K, Tanabe M, Takayanagi H, Cyong J, et al. Pharmacokinetic studies of lafutidime (FRG–8813) in man. Jpn Pharmacol Ther. 1995;23:3049–59.
Metadata
Title
Pharmacokinetic Properties of Oral Lafutidine Tablets and the Effect of Food on its Pharmacokinetics in Healthy Chinese Subjects
Authors
Shihong Li
Mingzhen Xu
Huqun Li
Juan Du
Weiyong Li
Publication date
01-10-2016
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 10/2016
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-016-0383-9

Other articles of this Issue 10/2016

Advances in Therapy 10/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.